{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:12:15Z","timestamp":1788469935003,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41571-024-00898-8","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T12:02:09Z","timestamp":1715083329000},"page":"563-564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CAR T cells in multiple myeloma: lessons learned"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-8221","authenticated-orcid":false,"given":"Vinay","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"898_CR1","unstructured":"US Food and Drug Administration. March 15, 2024: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. fda.gov, https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/march-15-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-03152024 (accessed 19 March 2024)."},{"key":"898_CR2","unstructured":"Sokolic, R. Oncologic Drugs Advisory Committee Meeting Introductory Comments. Ciltacabtagene Autoleucel. fda.org, https:\/\/www.fda.gov\/media\/177057\/download (2024)."},{"key":"898_CR3","unstructured":"Sokolic, R. Oncologic Drugs Advisory Committee Meeting Introductory Comments. Idecabtagene Vicleucel (ide-cel). fda.gov, https:\/\/www.fda.gov\/media\/177060\/download (2024)."},{"key":"898_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44770","volume":"5","author":"T Olivier","year":"2022","unstructured":"Olivier, T., Haslam, A. & Prasad, V. Reporting of physicians\u2019 or investigators\u2019 choice of treatment in oncology randomized clinical trials. JAMA Netw. Open 5, e2144770 (2022).","journal-title":"JAMA Netw. Open"},{"key":"898_CR5","unstructured":"ODAC. March 15, 2024 Oncologic Drugs Advisory Committe Meeting. fdazoomgov.com, https:\/\/go.nature.com\/4baYsLo (2024)."},{"key":"898_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10917-z","volume":"23","author":"T Olivier","year":"2023","unstructured":"Olivier, T., Haslam, A. & Prasad, V. Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020. BMC Cancer 23, 448 (2023).","journal-title":"BMC Cancer"},{"key":"898_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ejca.2021.07.036","volume":"156","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin, G. R. et al. Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: a systematic review and meta-analysis. Eur. J. Cancer 156, 164\u2013174 (2021).","journal-title":"Eur. J. Cancer"},{"key":"898_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","volume":"4","author":"I Hernandez","year":"2018","unstructured":"Hernandez, I., Prasad, V. & Gellad, W. F. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 4, 994\u2013996 (2018).","journal-title":"JAMA Oncol."},{"key":"898_CR9","unstructured":"Centers for Medicare & Medicaid Services. National Coverage Determination. Chimeric Antigen Receptor (CAR) T-cell therapy. 110.24. cms.gov, https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncd.aspx?ncdid=374 (accessed 22 April 2024)."},{"key":"898_CR10","unstructured":"Centers for Medicare & Medicaid Services. National Coverage Determination Process & Timeline. cms.gov, https:\/\/www.cms.gov\/cms-guide-medical-technology-companies-and-other-interested-parties\/coverage\/national-coverage-determination-process-timeline (accessed 19 March 2024)."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00898-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T13:07:33Z","timestamp":1721740053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00898-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["898"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00898-8","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"7 May 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.P. has acted as a consultant of OptumRX and UnitedHealthcare, receives research funding from Arnold Ventures through a grant made to UCSF, receives royalties for books and writing from Free Press, Johns Hopkins Press and MedPage and hosts the podcasts, <i>Plenary Session<\/i>, <i>Sensible Medicine<\/i> and <i>VPZD<\/i>, writes the newsletters <i>Sensible Medicine<\/i>, the <i>Drug Development Letter<\/i> and <i>VP\u2019s Observations and Thoughts<\/i>, and runs the YouTube channel <i>Vinay Prasad MD MPH<\/i>, which collectively earn revenue on the platforms Patreon, Substack and YouTube.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}